Читаем Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний полностью

Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

Бастиан Блоэм , Майкл Окун , Рэй Дорси , Тодд Шерер

80. Little MA, McSharry PE, Hunter EJ, Spielman J, Ramig LO. Suitability of dysphonia measurements for telemonitoring of Parkinson’s disease. IEEE Transactions on Biomedical Engineering. 2009;56(4):1015–1022; Tsanas A, Little MA, McSharry PE, Spielman J, Ramig LO. Novel speech signal processing algorithms for high-accuracy classification of Parkinson’s disease. IEEE Transactions on Biomedical Engineering. 2012;59(5):1264–1271; Tsanas A, Little MA, McSharry PE, Ramig LO. Accurate telemonitoring of Parkinson’s disease progression by noninvasive speech tests. IEEE Transactions on Biomedical Engineering. 2010;57(4):884–893; Tsanas A, Little MA, McSharry PE, Ramig LO. Nonlinear speech analysis algorithms mapped to a standard metric achieve clinically useful quantification of average Parkinson’s disease symptom severity. Journal of the Royal Society Interface. 2011;8(59):842–855.

81. Little MA. A test for Parkinson’s with a phone call [видео]. TED Global 2012. June 2012. www.ted.com/talks/max_little_a_test_for_ parkinson_s_with_a_phone_call. Accessed June 28, 2019.

82. Arora S, Venkataraman V, Zhan A, et al. Detecting and monitoring the symptoms of Parkinson’s disease using smartphones: a pilot study. Parkinsonism & Related Disorders. 2015;21(6):650–653.

83. Там же.

84. Zhan A, Mohan S, Tarolli C, et al. Using smartphones and machine learning to quantify Parkinson disease severity: the mobile Parkinson disease score. JAMA Neurology. 2018;75(7):876–880.

85. Bot BM, Suver C, Neto EC, et al. The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data. 2016;3:160011.

86. McLeonida. ResearchKit demo by Jeff Williams at Apple special event, March 2015 [видео]. YouTube. March 11, 2015. www.youtube.com/ watch?v=O0gcEFjQNGk. Accessed June 28, 2019.

87. Dorsey ER, Beck CA, Adams M, et al. Communicating clinical trial results to research participants. Archives of Neurology. 2008;65(12):1590–1595.

88. Writing Group for the NINDS Exploratory Trials in Parkinson Disease Investigators. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015;313(6):584–593.

89. Dorsey ER, Chan Y-FY, McConnell MV, Shaw SY, Trister AD, Friend SH. The use of smartphones for health research. Academic Medicine. 2017;92(2):157–160.

90. Turakhia MP, Desai M, Hedlin H, et al. Rationale and design of a largescale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study. American Heart Journal. 2019;207:66–75.

91. Farr C. The Apple Watch just got a lot better at tracking symptoms of Parkinson’s disease. CNBC. June 9, 2018. www.cnbc.com/2018/06/09/ apple-watch-adds-tech-to-track-parkinsons-disease.html. Updated June 10, 2018. Accessed November 10, 2018.

92. Collaboration with Verily aims to deepen Parkinson’s understanding through digital health tools. FoxFeed Blog. May 9, 2018. www.michaeljfox. org/news/collaboration-verily-aims-deepen-parkinsons-understanding-through-digital-health-tools?collaboration-with-verily-aims-to-deepen-parkinson-understanding-through-digital-health-tools=. Accessed June 28, 2019; About the study. Personalized Parkinson Project. www. parkinsonopmaat.nl/studie. Accessed May 20, 2019.

93. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline. Archives of Neurology. 2002;59(10): 1541–1550; Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurology. 2014;71(5):543–552.

94. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Affairs. 2006;25(2):420–428; Dorsey ER, Papapetropoulos S, Xiong M, Kieburtz K. The first frontier: digital biomarkers for neurodegenerative disorders. Digital Biomarkers. 2017;1(1):6-13; Dorsey ER, Venuto C, Venkataraman V, Harris DA, Kieburtz K. Novel methods and technologies for 21st-century clinical trials: a review. JAMA Neurology. 2015;72(5):582–588; CNS drugs take longer to develop and have lower success rates than other drugs [пресс-релиз]. Tufts Center for the Study of Drug Development. November 4, 2014. https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/tZ5aa 2bf604192023932fe1561/1520615264660/PR-NOVDEC14.pdf. Accessed June 28, 2019.

Перейти на страницу: